Drug Discovery AI News & Updates

Latent Labs Releases State-of-the-Art Web-Based AI Model for Novel Protein Design

Latent Labs launched LatentX, a web-based AI model that enables users to design entirely new proteins using natural language, achieving state-of-the-art performance in lab testing. Unlike AlphaFold which predicts existing protein structures, LatentX creates novel molecular designs including nanobodies and antibodies with precise atomic structures. The company plans to license the technology to academic institutions, biotech startups, and pharmaceutical companies to accelerate therapeutic development.

FutureHouse Launches 'Finch' AI Tool for Biology Research

FutureHouse, a nonprofit backed by Eric Schmidt, has released a biology-focused AI tool called 'Finch' that analyzes research papers to answer scientific questions and generate figures. The CEO compared it to a "first year grad student" that makes "silly mistakes" but can process information rapidly, though experts note AI's limited track record in scientific breakthroughs.

DeepMind Alumnus Launches Latent Labs with $50M to Revolutionize Computational Biology

Latent Labs, founded by former Google DeepMind scientist Simon Kohl, has emerged from stealth with $50 million in funding to build AI foundation models for computational biology. The startup aims to make biology programmable by developing models that can design and optimize proteins without extensive wet lab experimentation, potentially transforming the drug discovery process through partnerships with biotech and pharmaceutical companies.